

# CITATION REPORT

List of articles citing

## Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

DOI: [10.1007/s40273-018-0713-7](https://doi.org/10.1007/s40273-018-0713-7)

Pharmacoeconomics, 2019, 37, 333-343.

**Source:** <https://exaly.com/paper-pdf/74813467/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2	Cost-effectiveness and value of information analyses of Bruton's tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 28, 390-400	1.9	
1	An Investigation into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology. <b>2023</b> , 21, 385-394		0